日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Proton-pump inhibitors and palbociclib or abemaciclib in endocrine-sensitive breast cancer treatment

质子泵抑制剂联合帕博西尼或阿贝西利治疗内分泌敏感性乳腺癌

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-026-39093-3
Takada, Shinya; Takahashi, Kaori; Uozumi, Ryuji; Mukohara, Toru; Hayashida, Tetsu; Iwabe, Midori; Iihara, Hirotoshi; Kusuhara-Mamishin, Kanako; Tahatsu, Kanae; Kitagawa, Yuko; Tsuchiya, Masami; Kitahora, Mika; Umehara, Kengo; Nagayama, Aiko; Kosaka, Shinkichi; Asano-Niwa, Yoshimi; Watanabe, Kenichi; Seki, Tomoko; Ohnuki, Koji; Futamura, Manabu; Kawazoe, Hitoshi; Nakamura, Tomonori
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B)

BRCA1/2 逆转突变在日本转移性乳腺癌患者中发生，且在接受奥拉帕尼治疗后病情进展：OLIVE (WJOG15321B)

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-026-01855-2
Sakai, Hitomi; Kusumoto-Matsuo, Rika; Hosonaga, Mari; Nozawa, Kazuki; Futamura, Manabu; Tanabe, Yuko; Mukohara, Toru; Shiraishi, Kazuhiro; Toyama, Tatsuya; Yasojima, Hiroyuki; Watanabe, Noriyuki; Sakai, Hideki; Iwasa, Tsutomu; Takeuchi, Nobumichi; Tada, Hiroshi; Sakai, Kazuko; Chiba, Natsuko; Takano, Toshimi; Tsurutani, Junji
肿瘤
乳腺癌
肿瘤免疫
BRCA1
发表日期：2026
文献求助 收藏

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

更正：帕博西尼联合内分泌治疗对一线或二线治疗的 HR+/HER2- 晚期乳腺癌日本患者的总生存期：一项多中心观察性研究（P-BRIDGE 研究）

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-025-01787-3
Nagai, Shigenori E; Hattori, Masaya; Yoshinami, Tetsuhiro; Masuda, Hiroko; Okamura, Takuho; Watanabe, Kenichi; Nakayama, Takahiro; Tsuneizumi, Michiko; Takabatake, Daisuke; Harao, Michiko; Yoshino, Hiroshi; Mori, Natsuko; Yasojima, Hiroyuki; Oshiro, Chiya; Iwase, Madoka; Yamaguchi, Miki; Sangai, Takafumi; Sasada, Shinsuke; Ishida, Takanori; Futamura, Manabu; Muramatsu, Yasuaki; Kosaka, Nobuyoshi; Masuda, Norikazu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group

日本老年HR+/HER2-晚期乳腺癌患者接受帕博西尼联合内分泌治疗的真实世界疗效：P-BRIDGE研究按年龄分组的亚组分析

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-025-01812-5
Masuda, Hiroko; Nagai, Shigenori E; Hattori, Masaya; Yoshinami, Tetsuhiro; Okamura, Takuho; Watanabe, Kenichi; Nakayama, Takahiro; Tsuneizumi, Michiko; Takabatake, Daisuke; Harao, Michiko; Yoshino, Hiroshi; Mori, Natsuko; Yasojima, Hiroyuki; Oshiro, Chiya; Iwase, Madoka; Yamaguchi, Miki; Sangai, Takafumi; Sasada, Shinsuke; Ishida, Takanori; Futamura, Manabu; Oda, Hirotaka; Muramatsu, Yasuaki; Masuda, Norikazu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Impact of breast density on the efficacy of radiofrequency ablation in early-stage breast cancer

乳腺密度对早期乳腺癌射频消融疗效的影响

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-025-01775-7
Futamura, Manabu; Nagao, Yasuko; Takai, Yukiko; Niwa, Yoshimi; Nakakami, Akira; Okawa, Mai; Tokumaru, Yoshihisa; Mase, Junichi; Mori, Ryutaro; Watanabe, Daichi; Kinoshita, Takayuki; Matsuhashi, Nobuhisa
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Oncogenic functions of polypyrimidine tract-binding protein 1 in breast cancer metabolism and progression

多嘧啶束结合蛋白1在乳腺癌代谢和进展中的致癌功能

期刊:Biochemistry and Biophysics Reports
影响因子:2.2
doi:10.1016/j.bbrep.2026.102458
Futamura, Manabu; Tokumaru, Yoshihisa; Nakakami, Akira; Niwa, Yoshimi; Mase, Junichi; Sugiyama, Emiri; Okawa, Mai; Matsuda, Kana; Mori, Ryutaro; Akao, Yukihiro; Matsuhashi, Nobuhisa
肿瘤
肿瘤免疫
乳腺癌
代谢
发表日期：2026
文献求助 收藏

Application of N-NOSE for Evaluating the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

N-NOSE在评估乳腺癌患者新辅助化疗疗效中的应用

期刊:Cells
影响因子:5.2
doi:10.3390/cells14130950
Tokumaru, Yoshihisa; Niwa, Yoshimi; Mori, Ryutaro; Okawa, Mai; Nakakami, Akira; Sato, Yuta; Hatakeyama, Hideyuki; Hirotsu, Takaaki; di Luccio, Eric; Matsuhashi, Nobuhisa; Futamura, Manabu
肿瘤
乳腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

一线或二线治疗中，帕博西尼联合内分泌治疗对日本 HR+/HER2- 晚期乳腺癌患者的总生存期：一项多中心观察性研究（P-BRIDGE 研究）

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-025-01689-4
Nagai, Shigenori E; Hattori, Masaya; Yoshinami, Tetsuhiro; Masuda, Hiroko; Okamura, Takuho; Watanabe, Kenichi; Nakayama, Takahiro; Tsuneizumi, Michiko; Takabatake, Daisuke; Harao, Michiko; Yoshino, Hiroshi; Mori, Natsuko; Yasojima, Hiroyuki; Oshiro, Chiya; Iwase, Madoka; Yamaguchi, Miki; Sangai, Takafumi; Sasada, Shinsuke; Ishida, Takanori; Futamura, Manabu; Muramatsu, Yasuaki; Kosaka, Nobuyoshi; Masuda, Norikazu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26)

通过移动应用程序和可穿戴设备收集接受帕博西尼联合内分泌治疗或单独内分泌治疗的 HR +/HER2 - 晚期乳腺癌患者的健康相关生活质量和身体活动情况：6 个月纵向研究 (JBCRG-26)

期刊:Breast Cancer
影响因子:2.9
doi:10.1007/s12282-025-01744-0
Bando, Hiroko; Ueda, Aya; Terata, Kaori; Doi, Mihoko; Nagai, Shigenori E; Hattori, Masaya; Watanabe, Kenichi; Tamura, Nobuko; Futamura, Manabu; Koizumi, Kei; Niikura, Naoki; Miyaji, Tempei; Muramatsu, Yasuaki; Xu, Linghua; Masuda, Norikazu; Saji, Shigehira
肿瘤
HER2
肿瘤免疫
乳腺癌
BCR
发表日期：2025
文献求助 收藏

Urine-based nematode chemotaxis assay (N-NOSE) as a predictor of recurrence after curative surgery for resectable pancreatic cancer: preliminary data and single center experience

尿液线虫趋化性试验（N-NOSE）作为可切除胰腺癌根治术后复发的预测指标：初步数据和单中心经验

期刊:BMC Surgery
影响因子:1.8
doi:10.1186/s12893-025-03355-0
Fukada, Masahiro; Mitsui, Noriki; Horaguchi, Takeshi; Yasufuku, Itaru; Sato, Yuta; Tajima, Jesse Yu; Tanaka, Yoshihiro; Hatakeyama, Hideyuki; Alshammari, Aya Hasan; Morishita, Masayo; Hirotsu, Takaaki; di Luccio, Eric; Futamura, Manabu; Matsuhashi, Nobuhisa
胰腺癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏